Author:
Kim Hoon,Zheng Siyuan,Amini Seyed S.,Virk Selene M.,Mikkelsen Tom,Brat Daniel J.,Grimsby Jonna,Sougnez Carrie,Muller Florian,Hu Jian,Sloan Andrew E.,Cohen Mark L.,Van Meir Erwin G.,Scarpace Lisa,Laird Peter W.,Weinstein John N.,Lander Eric S.,Gabriel Stacey,Getz Gad,Meyerson Matthew,Chin Lynda,Barnholtz-Sloan Jill S.,Verhaak Roel G.W.
Abstract
Glioblastoma (GBM) is a prototypical heterogeneous brain tumor refractory to conventional therapy. A small residual population of cells escapes surgery and chemoradiation, resulting in a typically fatal tumor recurrence ∼7 mo after diagnosis. Understanding the molecular architecture of this residual population is critical for the development of successful therapies. We used whole-genome sequencing and whole-exome sequencing of multiple sectors from primary and paired recurrent GBM tumors to reconstruct the genomic profile of residual, therapy resistant tumor initiating cells. We found that genetic alteration of the p53 pathway is a primary molecular event predictive of a high number of subclonal mutations in glioblastoma. The genomic road leading to recurrence is highly idiosyncratic but can be broadly classified into linear recurrences that share extensive genetic similarity with the primary tumor and can be directly traced to one of its specific sectors, and divergent recurrences that share few genetic alterations with the primary tumor and originate from cells that branched off early during tumorigenesis. Our study provides mechanistic insights into how genetic alterations in primary tumors impact the ensuing evolution of tumor cells and the emergence of subclonal heterogeneity.
Funder
NCI
CPRIT
MD Anderson Genome Data Analysis Center
Publisher
Cold Spring Harbor Laboratory
Subject
Genetics(clinical),Genetics
Cited by
322 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献